
  
    
      
        Introduction_NNP
        The_DT clinical_JJ observation_NN that_IN sexual_JJ dimorphism_NN plays_VBZ a_DT
        role_NN in_IN the_DT immune_JJ response_NN suggests_VBZ that_IN the_DT endocrine_NN
        system_NN is_VBZ an_DT important_JJ factor_NN for_IN the_DT development_NN and_CC
        maintenance_NN of_IN the_DT response_NN ._. There_EX is_VBZ a_DT high_JJ frequency_NN of_IN
        autoimmune_JJ diseases_NNS in_IN females_NNS and_CC an_DT increased_VBN immune_JJ
        response_NN to_TO antigenic_JJ stimulus_NN ._. These_DT observations_NNS make_VBP it_PRP
        evident_JJ that_IN sexual_JJ dimorphism_NN probably_RB acts_VBZ on_IN the_DT immune_JJ
        response_NN through_IN its_PRP$ effect_NN upon_IN the_DT
        thymic-hypothalamic-pituitary-gonadic_JJ axis_NNS [_NN 1_CD ]_NN ._.
        Series_NNS of_IN subjects_NNS with_IN gonadal_NN dysgenesis_NNS ,_, and_CC isolated_VBD
        cases_NNS of_IN Klinefelter_NNP 's_POS syndrome_NN associated_VBN with_IN
        rheumatic_JJ /_NN autoimmune_JJ diseases_NNS (_( RAD_NNP )_) ,_, suggest_VBP a_DT relation_NN
        between_IN these_DT clinical_JJ conditions_NNS [_NN 2_CD ,_, 3_CD ]_NN ._. Among_IN male_JJ
        patients_NNS reported_VBD to_TO date_NN who_WP have_VBP hypogonadism_NN and_CC RAD_NNP are_VBP
        individuals_NNS with_IN systemic_JJ lupus_JJ erythematosus_JJ (_( SLE_NNP )_) [_NN 4_CD ,_, 5_CD ,_,
        6_CD ,_, 7_CD ]_NN ,_, lupus_JJ anticoagulant_NN and_CC antiphospholipid_NN syndrome_NN
        associated_VBN [_NN 8_CD ]_NN ,_, scleroderma_NN [_NN 9_CD ,_, 10_CD ,_, 11_CD ,_, 12_CD ]_NN ,_, rheumatoid_NN
        arthritis_NN (_( RA_NNP )_) [_NN 13_CD ]_NN ,_, ankylosing_VBG spondylitis_NNS (_( AS_NNP )_) [_NN 14_CD ,_, 15_CD ,_,
        16_CD ]_NN ,_, and_CC polymyositis_NNS [_NN 17_CD ]_NN ,_, while_IN Turner_NNP 's_POS syndrome_NN has_VBZ
        been_VBN associated_VBN with_IN autoimmune_JJ thyroiditis_NNS [_NN 3_CD ]_NN ,_, juvenile_JJ
        rheumatoid_NN arthritis_NN (_( JRA_NNP )_) [_NN 18_CD ]_NN ,_, and_CC juvenile-onset_JJ
        inflammatory_JJ bowel_NN disease_NN [_NN 19_CD ]_NN ._. Only_RB one_CD of_IN these_DT reports_NNS
        included_VBD eunuchoid_NN males_NNS and_CC female_JJ subjects_NNS with_IN an_DT
        abnormal_JJ X_NNP karyotype_NN [_NN 2_CD ]_NN ._.
        Our_PRP$ goal_NN in_IN the_DT present_JJ work_NN was_VBD to_TO determine_VB whether_IN
        male_JJ patients_NNS with_IN untreated_JJ hypogonadism_NN have_VBP an_DT increased_VBN
        risk_NN of_IN developing_VBG RAD_NNP ,_, and_CC ,_, if_IN so_RB ,_, whether_IN there_EX is_VBZ a_DT
        relation_NN to_TO the_DT type_NN of_IN hypogonadism_NN ._.
      
      
        Methods_NNP
        The_DT clinical_JJ criteria_NNS of_IN male_JJ hypogonadism_NN refers_VBZ to_TO
        failure_NN of_IN testicular_NN function_NN resulting_VBG in_IN decreased_VBD
        production_NN or_CC absence_NN of_IN male_JJ sex_NN hormones_NNS and_CC impaired_VBN
        spermatogenesis_NNS ,_, whether_IN this_DT failure_NN is_VBZ secondary_JJ to_TO
        hypothalamic_JJ and_CC pituitary_JJ dysfunction_NN or_CC is_VBZ primary_JJ
        testicular_NN failure_NN [_NN 20_CD ]_NN ._.
        From_IN 60_CD patients_NNS who_WP fulfilled_VBD the_DT previous_JJ hypogonadism_NN
        criteria_NNS who_WP were_VBD seen_VBN at_IN the_DT outpatient_NN Andrology_NNP Clinic_NNP ,_,
        Mexico_NNP City_NNP ,_, Mexico_NNP ,_, from_IN July_NNP 1998_CD to_TO May_NNP 2000_CD ,_, 13_CD who_WP
        were_VBD not_RB receiving_VBG hormone_NN substitution_NN were_VBD selected_VBN for_IN
        this_DT study_NN ._.
        The_DT clinical_JJ criteria_NNS of_IN male_JJ '_POS hypogonadism_NN '_'' refers_VBZ to_TO
        failure_NN of_IN testicular_NN function_NN resulting_VBG in_IN decreased_VBD
        production_NN or_CC absence_NN of_IN male_JJ sex_NN hormones_NNS and_CC impaired_VBN
        spermatogenesis_NNS ,_, whether_IN this_DT failure_NN is_VBZ secondary_JJ to_TO
        hypothalamic_JJ and_CC pituitary_JJ dysfunction_NN or_CC is_VBZ primary_JJ
        testicular_NN failure_NN [_NN 20_CD ]_NN ._.
        Ten_CD normogonadic_JJ healthy_JJ male_JJ hospital_NN staff_NN with_IN
        similar_JJ age_NN and_CC body_NN mass_NN index_NN [_NN 21_CD ]_NN constituted_VBD the_DT
        control_NN group_NN for_IN testicular_NN size_NN and_CC hormone_NN levels_NNS ._.
        All_DT the_DT patients_NNS gave_VBD their_PRP$ informed_VBN consent_NN ._. They_PRP and_CC
        the_DT control_NN subjects_NNS were_VBD given_VBN a_DT neuroendocrine_NN ,_, genetic_JJ ,_,
        and_CC clinic_NN evaluation_NN ,_, including_VBG a_DT physical_JJ exam_NN ,_, in_IN
        addition_NN to_TO computed_JJ tomography_NN of_IN the_DT sella_NN turcica_NN and_CC
        karyotyping_VBG of_IN peripheral_JJ leukocytes_NNS ._. The_DT presence_NN of_IN
        secondary_JJ sexual_JJ characteristics_NNS and_CC testicular_NN volume_NN
        (_( normal_JJ value_NN >_NN 20_CD ml_NN )_) were_VBD noted_VBN ._.
        In_IN the_DT patients_NNS ,_, the_DT rheumatolgic_JJ evaluation_NN included_VBD a_DT
        search_NN for_IN the_DT presence_NN of_IN diagnostic_JJ criteria_NNS for_IN SLE_NNP ,_, RA_NNP ,_,
        AS_NNP ,_, psoriatic_JJ arthritis_NN ,_, JRA_NNP ,_, polymyositis_NNS /_NN dermatomyositis_NNS ,_,
        scleroderma_NN /_NN CREST_NNP (_( calcinosis_NNS ,_, Raynaud_NNP 's_POS phenomenon_NN ,_,
        esophageal_NN dysfunction_NN ,_, sclerodactyly_RB ,_, telangiectasia_NN )_) ,_, and_CC
        Behcet_NNP 's_POS syndrome_NN [_NN 22_CD ]_NN ._. Venous_NNP blood_NN (_( 20_CD ml_NN )_) was_VBD extracted_VBN
        to_TO determine_VB the_DT erythrocyte_NN sedimentation_NN rate_NN (_( Wintrobe_NNP
        method_NN ,_, mm_NN /_NN h_NN )_) ,_, lupus_JJ erythematosus_JJ cells_NNS ,_, rheumatoid_NN factor_NN
        (_( normal_JJ value_NN <_NN 20_CD IU_NNP /_NN ml_NN )_) ,_, antinuclear_NN antibodies_NNS by_IN
        immunofluorescence_NN test_NN (_( rat_NN kidney_NN substrate_NN )_) ,_, anti-_NN DNA_NNP
        (_( radioimmunoassay_NN )_) ,_, and_CC Ro_NNP ,_, La_NNP ,_, Sm_NNP ,_, and_CC Scl-_NNP 70_CD by_IN
        nephelometry_NN to_TO disclose_VB autoimmune_JJ phenomena_NNS and_CC /_NN or_CC
        inflammatory_JJ serum_NN subclinical_JJ abnormalities_NNS ._. The_DT
        histocompatibility_NN antigen_NN B_NNP 27_CD (_( B_NNP 27_CD )_) was_VBD determined_VBN by_IN
        Terasaki_NNP 's_POS joint-to-thyroid_JJ function_NN test_NN (_( Cis_NNP bio_NN
        international_JJ Groupe_NNP ORIS_NNP Cedex-_NNP France_NNP )_) using_VBG
        radioimmunoassay_NN ._. Serum_NNP levels_NNS of_IN testosterone_NN
        (_( double-antibody_JJ radioimmunoassay_NN technique_NN )_) ,_, estradiol-_NN 17_CD β_NN
        (_( E_NNP 
        2_LS )_) (_( International_NNP CIS_NNP Sorin_NNP ,_, Paris_NNP ,_,
        France_NNP ;_: double-antibody_JJ radioimmunoassay_NN kit_NN )_) ,_,
        follicle-stimulating_JJ hormone_NN ,_, luteinizing_VBG hormone_NN ,_, and_CC
        prolactin_NN (_( Diagnostic_NNP Products_NNPS Co_NNP ,_, Los_NNP Angeles_NNP ,_, CA_NNP ,_, USA_NNP ;_:
        double-antibody_JJ radioimmunoassay_NN kit_NN )_) (_( in_IN duplicate_VB )_) were_VBD
        determined_VBN in_IN patients_NNS and_CC controls_NNS ._. Coefficients_NNP of_IN
        intra-assay_JJ and_CC interassay_NN variations_NNS were_VBD ,_, respectively_RB ,_,
        as_IN follows_VBZ :_: testosterone_NN ,_, 6_CD ._. 0_CD and_CC 10_CD ._. 4_LS %_NN ;_: E_NNP 
        2_CD ,_, 5_CD ._. 0_CD and_CC 8_CD ._. 5_CD %_NN ;_: follicle-stimulating_JJ
        hormone_NN ,_, 3_CD ._. 1_CD and_CC 7_CD ._. 7_CD %_NN ;_: luteinizing_VBG hormone_NN ,_, 7_CD ._. 0_CD and_CC 7_CD ._. 9_CD %_NN ;_:
        and_CC prolactin_NN ,_, 4_CD ._. 4_CD and_CC 8_CD ._. 6_CD %_NN ._. X-_NNP rays_NNS were_VBD made_VBN of_IN the_DT
        lumbosacral_NN spine_NN ,_, sacroiliac_NN joints_NNS ,_, and_CC affected_VBD
        peripheral_JJ joints_NNS and_CC were_VBD interpreted_VBN blind_JJ ._. Affected_NNP
        tissues_NNS were_VBD biopsied_JJ as_IN appropriate_JJ for_IN the_DT clinical_JJ
        signs_NNS ._.
        Fisher_NNP 's_POS exact_JJ test_NN and_CC the_DT Mann-_NNP Whitney_NNP 
        U_NNP test_NN were_VBD used_VBN for_IN statistical_JJ
        analysis_NN (_( computer_NN package_NN Epi-_NNP Info_NNP ,_, Version_NNP 6_CD ._. 00_CD ;_: Centers_NNPS
        for_IN Disease_NNP Control_NNP and_CC Prevention_NNP ,_, USA_NNP ,_, World_NNP Health_NNP
        Organization_NNP ,_, Geneva_NNP ,_, Switzerland_NNP )_) ._. The_DT significance_NN limit_NN
        was_VBD set_VBN at_IN 
        P_NN <_NN 0_CD ._. 05_CD ._.
      
      
        Results_NNS
        Age_NNP and_CC body_NN mass_NN index_NN were_VBD similar_JJ in_IN patients_NNS and_CC
        controls_NNS (_( mean_VB ±_NN standard_JJ deviation_NN )_) :_: respectively_RB ,_, age_NN
        25_CD ._. 3_LS ±_NN 8_CD ._. 4_CD years_NNS vs_NNS 29_CD ._. 5_LS ±_NN 7_CD ._. 6_CD years_NNS and_CC body_NN mass_NN index_NN
        23_CD ._. 1_LS ±_NN 3_CD ._. 3_CD kg_NN /_NN m_NN 2_CD vs_NNS 24_CD ._. 2_LS ±_NN 3_CD ._. 6_CD kg_NN /_NN m_NN 2_CD (_( 
        P_NN =_SYM NS_NNP )_) ._. The_DT testicular_NN volume_NN was_VBD 4_CD ._. 4_CD
        ±_NN 4_CD ._. 3_CD ml_NN in_IN patients_NNS and_CC 43_CD ._. 5_LS ±_NN 3_CD ._. 5_CD ml_NN in_IN controls_NNS (_( 
        P_NN =_SYM 0_CD ._. 001_CD )_) ._. Nine_CD of_IN the_DT 13_CD patients_NNS
        had_VBD hypergonadotropic_JJ hypergonadism_NN ,_, five_CD of_IN whom_WP had_VBD
        Klinefelter_NNP 's_POS syndrome_NN (_( 47_CD ,_, XXY_NNP )_) ._. The_DT other_JJ four_CD of_IN the_DT 13_CD
        patients_NNS had_VBD hypogonadotropic_JJ hypogonadism_NN (_( 46_CD ,_, XY_NNP )_) ;_: two_CD of_IN
        this_DT group_NN had_VBD Kallmann_NNP 's_POS syndrome_NN and_CC two_CD had_VBD idiopathic_JJ
        cryptorchidism_NN ._.
        Eight_CD out_IN of_IN the_DT 13_CD male_JJ hypogonadic_JJ patients_NNS also_RB had_VBD
        RAD_NNP independently_RB of_IN the_DT cause_NN of_IN their_PRP$ hypogonadism_NN ._. Of_IN
        these_DT ,_, four_CD had_VBD B_NNP 27_CD +_NN AS_NNP ,_, two_CD had_VBD SLE_NNP (_( in_IN one_CD case_NN
        associated_VBN with_IN anti-phospholipid_JJ antibodies_NNS )_) ,_, one_CD had_VBD JRA_NNP ,_,
        and_CC one_CD had_VBD juvenile_JJ dermatomyositis_NNS (_( Tables_NNP 1_CD and_CC 2_LS )_) ._. We_PRP
        did_VBD not_RB find_VB adult_NN RA_NNP ,_, scleroderma_NN ,_, scleroderma_NN /_NN CREST_NNP ,_,
        psoriatic_JJ arthritis_NN ,_, or_CC Behcet_NNP 's_POS syndrome_NN ._.
        Among_IN the_DT patients_NNS ,_, age_NN and_CC body_NN mass_NN index_NN were_VBD similar_JJ
        in_IN those_DT with_IN and_CC those_DT without_IN RAD_NNP ._. Serum_NNP testosterone_NN and_CC
        estradiol_NN 17_CD β_NN levels_NNS were_VBD lower_JJR in_IN those_DT with_IN RAD_NNP ,_, but_CC only_RB
        the_DT difference_NN in_IN testosterone_NN was_VBD highly_RB significant_JJ (_( 1_CD ._. 0_CD
        ±_NN 0_CD ._. 7_CD vs_NNS 2_CD ._. 7_CD ±_NN 1_CD ._. 2_CD ng_NN /_NN ml_NN ,_, 
        P_NN =_SYM 0_CD ._. 0005_CD )_) (_( see_VB Supplementary_NNP Table_NNP
        1_LS )_) ._.
      
      
        Discussion_NNP
        As_RB far_RB as_IN we_PRP know_VBP ,_, this_DT is_VBZ the_DT first_JJ report_NN of_IN an_DT
        intentional_JJ search_NN for_IN RAD_NNP in_IN male_JJ patients_NNS with_IN untreated_JJ
        hypogonadism_NN ._.
        Usually_RB ,_, males_NNS with_IN hypogonadism_NN diagnosed_VBN in_IN infancy_NN or_CC
        in_IN youth_NN are_VBP those_DT who_WP have_VBP a_DT complete_JJ hypogonadic_JJ clinical_JJ
        picture_NN ._. Some_DT individuals_NNS ,_, however_RB ,_, exhibit_NN an_DT incomplete_JJ
        clinical_JJ picture_NN and_CC may_MD reach_VB adulthood_NN without_IN having_VBG
        their_PRP$ condition_NN diagnosed_VBN ._. Their_PRP$ condition_NN may_MD come_VB to_TO
        light_VB during_IN tests_NNS of_IN sterility_NN in_IN a_DT couple_NN ,_, or_CC during_IN
        epidemiological_JJ studies_NNS [_NN 23_CD ,_, 24_CD ,_, 25_CD ,_, 26_CD ]_NN ,_, which_WDT have_VBP
        established_VBN the_DT frequency_NN of_IN male_JJ patients_NNS with_IN
        hypogonadism_NN ._.
        At_IN present_JJ ,_, it_PRP is_VBZ considered_VBN that_IN the_DT frequency_NN of_IN male_JJ
        patients_NNS with_IN hypogonadism_NN in_IN the_DT general_JJ male_JJ population_NN
        is_VBZ somewhere_RB between_IN 0_CD ._. 04_CD and_CC 1_CD %_NN [_NN 23_CD ,_, 24_CD ]_NN and_CC that_IN the_DT
        most_RBS frequent_JJ genetic_JJ alteration_NN found_VBD in_IN these_DT persons_NNS is_VBZ
        that_IN causing_VBG Klinefelter_NNP 's_POS syndrome_NN ,_, whose_WP$ prevalence_NN is_VBZ of_IN
        the_DT order_NN of_IN 0_CD ._. 02_CD to_TO 0_CD ._. 09_CD %_NN in_IN healthy_JJ populations_NNS [_NN 23_CD ,_, 24_CD ,_,
        25_CD ,_, 26_CD ]_NN and_CC 0_CD ._. 2_CD to_TO 41_CD ._. 3_LS %_NN in_IN populations_NNS with_IN certain_JJ mental_JJ
        or_CC behavioral_JJ problems_NNS [_NN 27_CD ,_, 28_CD ,_, 29_CD ]_NN ._.
        Our_PRP$ study_NN was_VBD performed_VBN in_IN a_DT smaller_JJR group_NN of_IN male_JJ
        patients_NNS with_IN hypogonadism_NN to_TO those_DT that_WDT have_VBP been_VBN reported_VBN
        previously_RB ,_, for_IN two_CD reasons_NNS ._. First_LS ,_, the_DT patients_NNS were_VBD
        studied_VBN in_IN an_DT andrology_NN clinic_NN for_IN infertility_NN and_CC thus_RB are_VBP
        not_RB an_DT unselected_JJ sample_NN of_IN the_DT general_JJ population_NN ._. Second_JJ ,_,
        their_PRP$ hypogonadism_NN had_VBD not_RB been_VBN diagnosed_VBN or_CC treated_VBN
        previously_RB ._. Although_IN it_PRP is_VBZ arguable_JJ that_IN our_PRP$ series_NN of_IN
        patients_NNS ,_, not_RB being_VBG a_DT representative_NN sample_NN ,_, is_VBZ unsuitable_JJ
        for_IN evaluation_NN of_IN the_DT frequency_NN of_IN RAD_NNP in_IN patients_NNS with_IN
        hypogonadism_NN ,_, we_PRP investigated_VBD RAD_NNP only_RB in_IN those_DT who_WP had_VBD not_RB
        been_VBN treated_VBN for_IN their_PRP$ hypogonadism_NN ,_, to_TO avoid_VB the_DT
        possibility_NN that_DT androgen_NN replacement_NN had_VBD interfered_VBD with_IN
        the_DT development_NN of_IN RAD_NNP [_NN 30_CD ,_, 31_CD ]_NN ._.
        Because_IN the_DT clinical_JJ picture_NN of_IN RAD_NNP in_IN some_DT of_IN the_DT
        patients_NNS was_VBD severe_JJ ,_, with_IN clear_JJ systemic_JJ and_CC articular_NN
        symptoms_NNS ,_, their_PRP$ RAD_NNP had_VBD been_VBN diagnosed_VBN elsewhere_RB ._. However_RB ,_,
        other_JJ patients_NNS with_IN hypogonadism_NN who_WP also_RB had_VBD JRA_NNP and_CC AS_NNP
        had_VBD only_RB a_DT few_JJ articular_NN symptoms_NNS ,_, so_RB slight_JJ that_IN the_DT RAD_NNP
        had_VBD gone_VBN unnoticed_JJ until_IN we_PRP looked_VBD for_IN it_PRP ._.
        Considering_VBG that_IN the_DT frequency_NN of_IN RAD_NNP in_IN Mexico_NNP City_NNP ,_,
        where_WRB our_PRP$ study_NN was_VBD performed_VBN ,_, is_VBZ about_IN 0_CD ._. 83_CD %_NN (_( including_VBG RA_NNP
        0_CD ._. 62_CD %_NN ;_: SLE_NNP 0_CD ._. 03_CD %_NN ;_: polymyositis_NNS /_NN dermatomyositis_NNS 0_CD ._. 04_CD %_NN ;_: JRA_NNP
        0_CD ._. 03_CD %_NN ;_: AS_NNP 0_CD ._. 01_CD %_NN ;_: and_CC other_JJ RAD_NNP [_NN Sjogren_NNP 's_POS syndrome_NN ,_, mix_NN
        connective_JJ tissue_NN disease_NN ,_, etc_FW ._. ]_NN ,_, 0_CD ._. 1_CD %_NN )_) [_NN 32_CD ]_NN ,_, the_DT
        relatively_RB large_JJ number_NN of_IN cases_NNS of_IN RAD_NNP in_IN this_DT very_RB small_JJ
        group_NN of_IN male_JJ patients_NNS with_IN untreated_JJ hypogonadism_NN was_VBD
        surprisingly_RB high_JJ (_( 
        P_NN <_NN 0_CD ._. 001_CD )_) ,_, suggesting_VBG a_DT strong_JJ
        relation_NN between_IN the_DT two_CD conditions_NNS (_( see_VB Supplementary_NNP
        Table_NNP 2_LS )_) ._. The_DT development_NN of_IN RAD_NNP only_RB in_IN those_DT patients_NNS
        with_IN severe_JJ testicular_NN dysfunction_NN suggests_VBZ that_IN such_JJ
        dysfunction_NN is_VBZ one_CD endogenous_JJ factor_NN that_IN predisposes_NNS to_TO
        the_DT development_NN of_IN RAD_NNP ._.
        The_DT disorder_NN most_RBS frequent_JJ in_IN our_PRP$ group_NN was_VBD the_DT
        combination_NN of_IN B_NNP 27_CD with_IN AS_NNP ._. The_DT frequency_NN of_IN patients_NNS with_IN
        B_NNP 27_CD (_( all_DT of_IN whom_WP also_RB developed_VBN AS_NNP )_) was_VBD very_RB high_JJ (_( 30_CD ._. 7_CD %_NN )_) ,_,
        leading_VBG to_TO the_DT conclusion_NN that_IN the_DT risk_NN that_IN males_NNS with_IN
        hypogonadism_NN will_MD develop_VB AS_NNP is_VBZ higher_JJR than_IN that_DT of_IN a_DT
        healthy_JJ Mexican_JJ mestizo_NN (_( about_IN 4_CD %_NN ,_, 
        P_NN =_SYM 0_CD ._. 001_CD )_) [_NN 33_CD ]_NN ._. We_PRP cannot_NN explain_VBP
        this_DT association_NN at_IN present_NN ._.
        The_DT frequency_NN of_IN SLE_NNP in_IN male_JJ patients_NNS with_IN hypogonadism_NN
        was_VBD higher_JJR than_IN would_MD be_VB expected_VBN in_IN the_DT general_JJ
        population_NN ._. Despite_IN the_DT increased_VBN odds_NNS ratio_NN for_IN the_DT
        development_NN of_IN SLE_NNP in_IN such_JJ patients_NNS ,_, the_DT confidence_NN
        interval_NN was_VBD very_RB wide_JJ ,_, suggesting_VBG that_IN other_JJ factors_NNS in_IN
        addition_NN to_TO hormonal_NN and_CC genetic_JJ alterations_NNS affect_VBP the_DT
        development_NN of_IN SLE_NNP in_IN these_DT patients_NNS ._.
        Our_PRP$ group_NN of_IN patients_NNS includes_VBZ ,_, as_RB far_RB as_IN we_PRP know_VBP ,_, the_DT
        first_JJ case_NN of_IN hypogonadism_NN associated_VBN with_IN juvenile_JJ
        dermatomyositis_NNS ._. The_DT development_NN of_IN dermatomyositis_NNS and_CC JRA_NNP
        was_VBD higher_JJR in_IN our_PRP$ patients_NNS than_IN in_IN the_DT general_JJ population_NN (_(
        
        P_NN =_SYM 0_CD ._. 006_CD and_CC 
        P_NN =_SYM 0_CD ._. 004_CD ,_, respectively_RB ;_:
        Supplementary_NNP Table_NNP 2_LS )_) ._. Nevertheless_RB ,_, the_DT confidence_NN
        interval_NN was_VBD not_RB calculable_JJ ;_: therefore_RB we_PRP conclude_VBP that_IN
        these_DT associations_NNS are_VBP coincidental_JJ ._. The_DT fact_NN that_DT
        frequency_NN of_IN RA_NNP was_VBD no_DT higher_JJR in_IN our_PRP$ group_NN of_IN patients_NNS than_IN
        in_IN the_DT general_JJ population_NN suggests_VBZ that_IN the_DT RA_NNP and_CC
        hypogonadism_NN are_VBP not_RB related_VBN ,_, as_IN has_VBZ already_RB been_VBN suggested_VBN
        [_NN 13_CD ]_NN ._.
        Because_IN the_DT group_NN of_IN patients_NNS we_PRP studied_VBD was_VBD so_RB
        heterogeneous_JJ (_( hypogonadism_NN due_JJ to_TO various_JJ causes_NNS ,_, and_CC
        various_JJ RAD_NNP )_) ,_, we_PRP can_MD conclude_VB only_RB that_IN the_DT hypogonadism_NN
        itself_PRP (_( regardless_RB of_IN its_PRP$ particular_JJ etiology_NN )_) and_CC the_DT very_RB
        low_JJ serum_NN testosterone_NN levels_NNS are_VBP associated_VBN with_IN the_DT
        increased_VBN frequency_NN of_IN RAD_NNP ._.
        Studies_NNS in_IN healthy_JJ ,_, normogonadic_JJ males_NNS with_IN RAD_NNP have_VBP
        found_VBN low_JJ serum_NN levels_NNS of_IN testosterone_NN and_CC high_JJ levels_NNS of_IN E_NNP
        
        2_LS in_IN patients_NNS with_IN RA_NNP ,_, SLE_NNP ,_, and_CC
        Sjogren_NNP 's_POS syndrome_NN [_NN 34_CD ,_, 35_CD ]_NN ._. The_DT inflamed_JJ tissues_NNS of_IN
        normogonadic_JJ patients_NNS with_IN RAD_NNP contain_VB intense_JJ cellular_JJ
        infiltrates_NNS rich_JJ in_IN macrophages_NNS ._. These_DT cells_NNS have_VBP hormonal_NN
        receptors_NNS capable_JJ of_IN converting_VBG testosterone_NN and_CC
        androstenedione_NN into_IN estrone_NN and_CC E_NNP 
        2_CD by_IN means_NNS of_IN aromatase_NN [_NN 36_CD ,_, 37_CD ,_, 38_CD ]_NN ._.
        An_DT increase_NN in_IN the_DT activity_NN of_IN aromatase_NN induced_VBN locally_RB
        could_MD explain_VB the_DT drop_NN in_IN androgen_NN levels_NNS and_CC the_DT increase_NN
        in_IN estrogens_NNS observed_VBD in_IN patients_NNS with_IN RA_NNP [_NN 38_CD ]_NN ._. However_RB ,_,
        in_IN our_PRP$ group_NN of_IN patients_NNS ,_, serum_NN testosterone_NN and_CC E_NNP 
        2_CD were_VBD both_DT decreased_VBD ._. Therefore_RB ,_, in_IN our_PRP$
        hypogonadic_JJ male_JJ patients_NNS ,_, the_DT main_JJ cause_NN of_IN the_DT
        testosterone_NN decrease_NN was_VBD not_RB due_JJ to_TO an_DT increase_NN in_IN its_PRP$
        conversion_NN to_TO E_NNP 
        2_CD because_IN the_DT gonadal_NN failure_NN caused_VBD a_DT
        decrease_NN of_IN both_DT hormones_NNS ,_, mainly_RB of_IN the_DT testosterone_NN ,_,
        without_IN showing_VBG an_DT increment_NN from_IN its_PRP$ conversion_NN to_TO E_NNP 
        2_CD ._. Although_IN the_DT effects_NNS of_IN low_JJ serum_NN
        testosterone_NN levels_NNS on_IN the_DT immune_JJ system_NN have_VBP been_VBN little_RB
        studied_VBN ,_, Bebo_NNP 
        et_CC al_NN ._. have_VBP shown_VBN that_DT orchidectomy_NN
        in_IN mice_NNS can_MD diminish_VB the_DT flow_NN of_IN CD_NNP 4_CD +_NN activated_VBN in_IN
        experimental_JJ autoimmune_JJ encephalomyelitis_NNS [_NN 39_CD ]_NN ._. In_IN humans_NNS ,_,
        before_IN treatment_NN with_IN androgens_NNS ,_, patients_NNS who_WP have_VBP
        Klinefelter_NNP 's_POS syndrome_NN but_CC not_RB RAD_NNP have_VB very_RB diminished_VBN
        levels_NNS of_IN testosterone_NN associated_VBN with_IN high_JJ levels_NNS of_IN IgG_NNP ,_,
        IgA_NNP ,_, IgM_NNP ,_, IL-_NNP 2_CD ,_, and_CC IL-_NNP 4_CD and_CC with_IN an_DT absolute_JJ increase_NN of_IN
        CD_NNP 3_CD +_NN ,_, CD_NNP 4_CD +_NN ,_, and_CC the_DT CD_NNP 4_CD +_NN /_NN CD_NNP 8_CD +_NN ratio_NN [_NN 30_CD ]_NN ._. In_IN patients_NNS
        who_WP have_VBP both_DT Klinefelter_NNP 's_POS syndrome_NN and_CC RAD_NNP ,_, the_DT
        diminished_VBN level_NN of_IN testosterone_NN is_VBZ associated_VBN with_IN low_JJ
        percentages_NNS of_IN OKT_NNP 3_CD +_NN and_CC OKT_NNP 8_CD +_NN and_CC with_IN an_DT increase_NN of_IN the_DT
        OKT_NNP 4_CD /_NN OKT_NNP 8_CD ratio_NN [_NN 31_CD ]_NN ._. On_IN the_DT basis_NN of_IN our_PRP$ findings_NNS and_CC of_IN
        the_DT reports_NNS cited_VBD ,_, we_PRP conclude_VBP that_DT lack_NN of_IN testosterone_NN
        increases_NNS humoral_NN and_CC cellular_JJ immunity_NN ._. When_WRB androgens_NNS are_VBP
        given_VBN ,_, these_DT abnormalities_NNS are_VBP reversed_VBN and_CC the_DT clinical_JJ
        picture_NN improves_VBZ [_NN 30_CD ,_, 31_CD ]_NN ._.
        If_IN our_PRP$ argument_NN is_VBZ correct_JJ ,_, low_JJ serum_NN testosterone_NN
        levels_NNS favor_VBP the_DT development_NN of_IN RAD_NNP in_IN the_DT hypogonadic_JJ male_JJ
        patient_NN ,_, while_IN in_IN the_DT normogonadic_JJ male_JJ who_WP develops_VBZ RAD_NNP
        (_( mainly_RB in_IN RA_NNP )_) the_DT decrease_NN of_IN testosterone_NN serum_NN levels_NNS is_VBZ
        due_JJ to_TO an_DT increase_NN in_IN its_PRP$ metabolism_NN for_IN the_DT activated_VBN
        immune_JJ system_NN ,_, with_IN the_DT subsequent_JJ elevation_NN of_IN E_NNP 
        2_CD ._. These_DT differences_NNS could_MD also_RB explain_VB
        the_DT low_JJ or_CC almost_RB null_NN association_NN of_IN RA_NNP and_CC hypogonadism_NN [_NN
        13_CD ]_NN ._. In_IN both_DT cases_NNS ,_, after_IN androgens_NNS are_VBP given_VBN ,_, the_DT clinical_JJ
        picture_NN and_CC the_DT abnormalities_NNS of_IN the_DT immune_JJ system_NN are_VBP
        ameliorated_JJ [_NN 30_CD ,_, 31_CD ,_, 38_CD ]_NN ._.
        In_IN summary_NN ,_, males_NNS who_WP have_VBP hypogonadism_NN ,_, regardless_RB of_IN
        its_PRP$ cause_NN ,_, develop_VB RAD_NNP more_RBR frequently_RB than_IN the_DT general_JJ
        population_NN ,_, when_WRB they_PRP have_VBP very_RB low_JJ serum_NN levels_NNS of_IN
        testosterone_NN ._.
      
      
        Abbreviations_NNP
        AS_NNP =_SYM ankylosing_VBG spondylitis_NNS ;_: B_NNP 27_CD =_SYM histocompatibility_NN
        antigen_NN B_NNP 27_CD ;_: CREST_NNP =_SYM calcinosis_NNS ,_, Raynaud_NNP 's_POS phenomenon_NN ,_,
        esophageal_NN dysfunction_NN ,_, sclerodactyly_RB ,_, telangiectasia_NN ;_: E_NNP 
        2_CD =_SYM estradiol-_NN 17_CD β_NN JRA_NNP =_SYM juvenile_JJ
        rheumatoid_NN arthritis_NN ;_: RA_NNP =_SYM rheumatoid_NN arthritis_NN ;_: RAD_NNP =_SYM
        rheumatic_JJ /_NN autoimmune_JJ disease_NN ;_: SLE_NNP =_SYM systemic_JJ lupus_JJ
        erythematosus_JJ ._.
      
    
  
